PerformancePEGylated MGFPEGylated Mechano-Growth Factor

PEG-MGF

PEGylated Mechano-Growth Factor · long-acting conjugate of the MGF E-domain peptide

PEG-MGF is MGF (Mechano-Growth Factor) with a polyethylene-glycol (PEG) chain attached to make it last longer in the body. Plain MGF breaks down very quickly, so it only works as a brief local pulse; the PEG chain shields it from enzymes and kidney clearance, turning it into a longer-acting, more systemic version — the design opposite of the short, local parent. Two honesty notes matter: MGF's core mechanism is itself contested, and almost all the underlying research used unmodified MGF, not the PEGylated form, so there is essentially no primary science on the conjugate itself. It is a research reagent with no approved human use, no human trials, and is prohibited in sport (WADA).

The short version

PEG-MGF is the longer-lasting cousin of MGF. MGF is a short peptide proposed to act as a local muscle-repair signal, but on its own it falls apart in the body within minutes, so its effect would only ever be a quick, nearby pulse.

"PEGylation" fixes the lasting-power problem: chemists attach a strand of polyethylene glycol (PEG) — a safe, water-loving polymer used in many approved drugs — to the peptide. That strand acts like a shield, slowing the enzymes and kidneys that would normally clear the peptide, so a PEGylated version circulates much longer and can act through the whole body rather than just at the injection spot.

Two honesty notes. First, MGF's basic mechanism is genuinely disputed (an independent lab found the synthetic peptide did nothing unique). Second, almost all of the research that exists was done on plain MGF, not the PEGylated form — so claims specific to PEG-MGF are largely untested. It is sold as a research reagent, not a medicine, has no human trials, and is banned in sport.

Molecular identity

Specs

Peptide core: MGF E-domain, 24 AA (IGF-1Ec splice-variant C-terminal peptide)PubChem CID 175675731
Core sequence (24 AA): YQPPSTNKNTKSQRRKGSTFEERKPubChem CID 175675731
Core molecular formula: C121H199N41O40 (unmodified peptide core, before PEG)PubChem CID 175675731
Core molecular weight: 2,868.1 g/mol (unmodified core; conjugate is heavier)PubChem CID 175675731
PEG attachment: Variable — chain size/branching not standardized; no fixed conjugate formula, MW, CAS, or PubChem CIDManufacturer-dependent
Structure / class: PEGylated conjugate of the MGF E-domain peptide; PEG slows enzymatic/renal clearancePMID 27775236
Molecular target: Proposed (still-unidentified) MGF receptor — same contested mechanism as unmodified MGFPMID 24253050
Half-life: Longer than unmodified MGF (PEGylation rationale); no sourced human PK figurePMID 27775236
Regulatory status: Research reagent; not FDA-approved; prohibited in sport (WADA S2, growth factors; mechano growth factors named)WADA Prohibited List

Plain English

Mechanism

PEG-MGF is meant to do whatever MGF does, but for longer and more systemically. The proposed biology is identical to MGF's: the MGF peptide is the unique "E-domain" tail of a mechanically-triggered IGF-1 splice variant, theorized to activate satellite cells (muscle stem cells) and kick-start local repair through a still-unidentified receptor. That mechanism is contested and should be read as a hypothesis — see MGF for the full counter-evidence, including an independent study that found no unique activity for the synthetic peptide.

What PEGylation changes is not the biology but the lifespan. Attaching a polyethylene-glycol chain increases the molecule's effective size and surrounds it with a watery shell, which slows two things that destroy plain MGF fast: enzymatic breakdown in the blood and filtration by the kidneys. The intended result is a peptide that survives long enough to reach tissues throughout the body and to be dosed less often — converting MGF's brief, local pulse into sustained, systemic exposure.

The critical caveat: this lasting-power rationale is well-established PEGylation chemistry, but it has not been validated for this specific conjugate in published studies, and the popular 'several-day half-life' figure cannot be traced to a primary human source.

Sources:PMID 20130113 PMID 24253050 PMID 27775236

Why people reach for it

Potential benefits

PEG-MGF is reached for as the longer-acting, systemic version of MGF — fewer injections, whole-body reach. Two honesty notes apply: MGF's base mechanism is contested, and the PEGylated conjugate itself is essentially unstudied.

A longer-lasting take on MGF's repair signal — Its headline appeal. The PEG chain shields the peptide from the enzymes and kidneys that clear plain MGF within minutes, so it's reached for when people want MGF's proposed satellite-cell signal to persist instead of firing and fading fast.
Fewer injections, systemic coverage — Because it lasts longer, it's dosed only about twice a week and is meant to act throughout the body rather than at one site — the convenient, hands-off counterpart to plain MGF's frequent peri-workout pulse.
Less dependent on perfect timing — With sustained exposure across days, the tight train-immediately-then-inject demand of plain MGF relaxes — weekly training volume does the work rather than any single session's clock, which people find easier to run.
A systemic base for an IGF stack — Used as the all-week background ahead of an IGF proliferation signal — most coherently IGF-1 LR3 or a local IGF-1 DES pulse — with satellite-cell activation proposed to hand off to IGF-driven proliferation.
Honest caveat: largely untested — Almost all the underlying biology used plain MGF, not the PEGylated form, and MGF's mechanism is itself disputed — plus repeat PEG dosing can raise anti-PEG antibodies — so this is a compound people experiment with, not one with established benefits.

Sources:PMID 20130113 PMID 24253050 PMID 27775236

What people reach for PEG-MGF for, drawn from the PEGylation rationale and a contested MGF hypothesis (the conjugate itself essentially unstudied) and how it's used — not proven outcomes or medical claims.

Implied timing

Best time to dose

Implied best time

Post-workout

Most people dose PEG-MGF post-workout on training days — but because PEGylation makes it long-acting and systemic, the exact timing relative to training matters far less than it does for plain MGF.

PEG-MGF carries the same proposed post-damage repair signal as MGF, so a post-workout dose still lines it up with the training stimulus it's meant to amplify — post-workout is the sensible anchor.
But the PEG chain extends its action across days, so it works systemically rather than as a tight local pulse — meaning a missed-by-a-few-hours dose doesn't lose the window the way short-acting plain MGF would. It's dosed far less frequently (about 2–3×/week) than MGF for exactly this reason.
Because the design is sustained coverage, many users simply pick a consistent time on training or off days; the accumulation of weekly training volume, not any single session's timing, is what the molecule has to work with.
There's no circadian or food constraint driving the hour — subcutaneous injection bypasses gut absorption — so consistency across the cycle matters more than the exact clock time.

No study establishes an ideal time of day for PEG-MGF — this is reasoned from the PEGylation rationale and how it's used. Most peptide dosing lands in the midday-to-evening window; for PEG-MGF a post-workout slot is the natural anchor, but its long action makes exact timing far less critical than for plain MGF.

Sources:PMID 20130113 PMID 27775236

How to run it

Dosing & protocol

PEG-MGF is dosed as a subcutaneous injection — the research-peptide form, and the route the on-page calculator is built for. There is no published human trial setting a safe or effective dose, so the ranges and schedule below are community-and-practitioner convention built on the PEGylation rationale: fewer doses, systemic coverage, versus plain MGF's frequent peri-workout pulse. Read it as a map of how the user community approaches PEG-MGF — not a validated prescription.

Triple uncertainty: (1) MGF's core mechanism is contested — an independent replication found no unique activity for the synthetic peptide; (2) essentially all primary research used unmodified MGF, not the PEGylated conjugate; (3) repeated PEGylated dosing can raise anti-PEG antibodies. Every number here is convention layered on a doubly-unstudied compound.

Tiered dose ranges

Because PEG-MGF is meant for systemic, sustained exposure, doses are lower and less frequent than plain MGF.

Low / introductory:: 200 mcg per dose, 2×/week — used when first running PEG-MGF or combining it with other IGF-axis peptides where cumulative load matters.
Standard:: 200–400 mcg per dose, 2–3×/week — the most common community range for muscle-repair and recovery goals.
Upper end:: 400 mcg per dose, 3×/week — used in heavier cycle designs; this is the ceiling of common practice before IGF-axis cautions (hypoglycemia, proliferation) become relevant.

Subcutaneous administration

PEG-MGF is injected into subcutaneous fat; unlike plain MGF, site-specific targeting is not the goal — systemic coverage is.

Injection site:: Abdomen (a couple of inches from the navel), outer thigh, or love-handle area. Rotate between sites across doses to avoid local irritation and lipohypertrophy.
Measuring the dose:: Drawn on a U-100 insulin syringe from the reconstituted vial. On the default 2 mg vial + 2 mL BAC water mix (1,000 mcg/mL): 200 mcg = 20 IU · 300 mcg = 30 IU · 400 mcg = 40 IU. The calculator handles any vial size.
Timing:: A post-workout dose on training days is the sensible anchor — see Best time to dose above — but because PEG-MGF's point is sustained systemic exposure, not a tight post-training local pulse like plain MGF, the exact time of injection relative to training is far less critical. Many users pick a consistent time on training or off days to maintain steady coverage.
Food window:: Subcutaneous injection bypasses GI absorption entirely, so PEG-MGF can be injected independent of meals. If combining with IGF-axis partners, check each partner's food-window guidance (IGF-1 LR3 is often taken fasted).

Cycle & washout

PEG-MGF is almost always run in a bounded cycle rather than continuously — the longer-acting design doesn't change that pattern.

Standard cycle:: 4–6 weeks of 2–3×/week dosing. Some users run a shorter 2–4 week window when pairing with IGF-1 LR3 or MGF in a structured block.
Washout:: Follow with a 4-week minimum break. The anti-PEG antibody consideration makes longer gaps between PEG-MGF cycles more relevant here than for most peptides — repeated exposure without breaks may build a more robust immune response over time.
Placement in a stack:: When run alongside plain MGF, PEG-MGF is typically started first (or concurrently at the cycle's start) to establish systemic background, with plain MGF added around training sessions for the local pulse.

Reconstitution at a glance

The on-page calculator does this live; quick reference for the default 2 mg vial:

Mixing:: 2 mg vial + 2 mL bacteriostatic water = 1,000 mcg per mL. On a 100-unit (1 mL) insulin syringe: 200 mcg = 20 IU · 300 mcg = 30 IU · 400 mcg = 40 IU.
Why this dilution:: The 1:1 mg-to-mL ratio keeps syringe units at a readable scale for the 200–400 mcg dose range — no sub-10-IU measurements where errors compound.

Sources:PMID 20130113 PMID 24253050 PMID 27775236

Substrate the signal needs

Nutritional cofactor precision

PEG-MGF is theorized to carry a sustained, systemic satellite-cell activation signal across the week — not a single peri-workout pulse like plain MGF. That design dictates a different cofactor approach: feed the signal continuously, train broadly across the week, and flag the one honest pharmacological caution (anti-PEG antibodies). Every recommendation below traces to PEG-MGF's longer-acting, systemic character, not to a PEG-MGF nutrition study.

Reasoned from PEG-MGF's extended-exposure, systemic design plus satellite-cell and IGF-axis biology — not a PEG-MGF cofactor study. The mechanism PEG-MGF is supposed to act through is itself contested; these cofactors support the substrate and context that would amplify the effect if that mechanism holds.

Supply the substrate — steady daily protein + leucine

The single most load-bearing cofactor: a prolonged satellite-cell signal needs a continuous amino-acid supply to drive protein synthesis, not just a post-workout window.

Why it's different from plain MGF:: Plain MGF's brief local pulse is typically paired with a peri-workout protein hit; PEG-MGF's multi-day systemic exposure means the signal is present around the clock — so gaps in amino-acid availability (fasted stretches, low-protein days) become more relevant. The satellite-cell signal cannot convert to new muscle protein without the raw material.
Protocol:: 1.8–2.2 g protein per kg bodyweight per day (≈ 0.8–1.0 g/lb), distributed across 3–5 meals or shakes — each containing at least 3 g leucine to reliably trigger mTOR and muscle protein synthesis. This is daily baseline, not a pre/post-workout loading strategy.
Leucine specifically:: Leucine is the amino acid that flips the mTOR switch — without ≥ 3 g per sitting, protein synthesis is sub-maximally stimulated. With PEG-MGF's longer exposure, every feeding window is a potential amplification point, not just the post-training window.

Amplify — distributed resistance training across the week

PEG-MGF's longer half-life relaxes the tight training-to-dose timing that makes plain MGF demanding; the amplifier becomes consistent mechanical loading across the week.

Mechanism:: Satellite cells are activated by mechanical strain — the training stimulus is what the signal is supposed to act on. With plain MGF, users try to inject immediately post-workout for the brief peri-wound pulse. With PEG-MGF, the peptide is theoretically present across multiple training sessions, so the accumulation of weekly training volume rather than any single session's timing is what the molecule has to work with.
Protocol:: Progressive resistance training 3–5×/week targeting the muscle groups of interest. There is no strict need to time PEG-MGF injections to individual sessions — the design rationale is that sustained systemic coverage does the timing work automatically. Sleep (7–9 hours) is where the repair stimulus executes; adequate total caloric surplus on training days rounds out the amplification picture.

Mitigate — anti-PEG immunogenicity awareness

There is no nutritional or pharmacological countermeasure for anti-PEG antibody development — the honest mitigation is behavioral: cycle structure and product awareness.

The concern:: Repeated exposure to PEGylated compounds can trigger anti-PEG antibodies (also called pre-existing anti-PEG antibodies are common in the general population from food/cosmetics exposure). These antibodies can accelerate clearance of the drug, reduce effect over repeated cycles, and in rare cases cause hypersensitivity. This is a recognized, general PEGylation pharmacology concern — not PEG-MGF-specific, but fully applicable.
Practical mitigation:: Keep cycles bounded (4–6 weeks) with meaningful gaps between them (4+ weeks). If other PEGylated products are in the stack (some PEG-GH formulations, PEGylated interferons), cumulative PEG exposure compounds the antibody-induction risk — space cycles or avoid stacking PEGylated compounds simultaneously. There is no supplement that reliably blocks anti-PEG antibody formation.
Micronutrient support:: The standard IGF/GH-axis support micronutrient set applies here as it does to any satellite-cell-adjacent peptide: zinc 25–50 mg/day (enzyme cofactor in the repair cascade), magnesium 300–400 mg/day (sleep quality and muscle function), vitamin D to sufficient blood levels (immune and muscle fiber regulation), vitamin C 500–1,000 mg/day (collagen crosslinking in connective tissue alongside the muscle). These trace to IGF-axis biology generally, not to anti-PEG mitigation.

Combinations + timing

Stacking notes + timing windows

PEG-MGF's defining feature is duration and systemic reach. Its best stack partners bring the complementary angles it lacks: the short local peri-workout pulse (MGF), or the downstream IGF proliferation step (IGF-1 LR3 / IGF-1 DES) that satellite-cell activation is supposed to hand off to. Pairing PEG-MGF with another PEGylated peptide or a second growth signal that works the same lever would be redundant — and adds compound anti-PEG antibody exposure.

Triple uncertainty on every stack here: MGF's base mechanism is contested; the PEGylated conjugate is essentially unstudied; and repeat PEGylated dosing can build anti-PEG antibodies. These are community protocols reasoned from complementary mechanisms — not regimens with human trial data. "Reached for" describes where users go, not a proven indication.

PEG-MGF + MGF

The duration stack — long systemic baseline (PEG-MGF) layered with a short peri-workout local pulse (MGF).

Why it works:: MGF is meant to fire at the site of mechanical damage in the minutes after a training session — a brief local satellite-cell activation pulse. PEG-MGF is meant to hold a lower, steady systemic signal across the days between sessions. The theory is that the two complement without overlapping: local + immediate versus systemic + sustained. Neither replaces the other because they operate on opposite timescales.
The protocol:: PEG-MGF 200–400 mcg SC 2–3×/week at a consistent non-session-timed window; MGF 100–200 mcg SC within 30 minutes post-training on training days only, injected near the worked muscle group. Run concurrently; the peri-workout window of MGF is the differentiator — PEG-MGF does not need to match it.
Outcome:: Reached for on muscle-building and hypertrophy-recovery cycles where users want both the local post-workout signal and a persistent background. The most common PEG-MGF pairing in community practice.

PEG-MGF + IGF-1 LR3

The satellite-cell-to-proliferation handoff — activation (PEG-MGF) paired with the IGF downstream signal (IGF-1 LR3).

Why it works:: In the proposed biology, MGF/PEG-MGF is theorized to activate quiescent satellite cells; IGF-1 LR3 then drives those activated cells to proliferate and differentiate into new muscle fibers. The two steps are sequential in the repair cascade, not parallel — so the peptides target different points on the same pathway rather than doubling up. IGF-1 LR3's long-acting design (similarly extended versus native IGF-1) also fits naturally alongside PEG-MGF's infrequent-dose schedule.
The protocol:: PEG-MGF 200–400 mcg SC 2–3×/week; IGF-1 LR3 20–60 mcg SC once daily or on training days only, typically taken fasted or in the morning before the first meal. Keep IGF-1 LR3 cycles short (4 weeks) because of its potency and proliferative signaling; PEG-MGF can run the same block or be staggered.
Outcome:: Reached for on aggressive hypertrophy blocks where users are trying to stack multiple IGF-axis signals. The IGF-axis cautions apply in full: hypoglycemia risk (carry fast carbs), and the theoretical proliferation concern (no long-duration data in humans).

PEG-MGF + IGF-1 DES

The local-plus-systemic IGF combination — IGF-1 DES's local potency alongside PEG-MGF's systemic reach.

Why it works:: IGF-1 DES is a truncated IGF-1 fragment (IGF-1 minus the first three amino acids) that binds IGF-1 receptors without competitive inhibition from binding proteins — it acts locally at the injection site with higher receptor affinity and shorter duration than IGF-1 LR3. Pairing it with PEG-MGF follows the same local/systemic logic as the MGF + PEG-MGF stack: IGF-1 DES for the targeted local IGF signal at the worked muscle, PEG-MGF for the whole-body satellite-cell background.
The protocol:: PEG-MGF 200–400 mcg SC 2–3×/week at any consistent time; IGF-1 DES 50–150 mcg SC post-training injected near the target muscle group on training days. IGF-1 DES's shorter window means it is typically paired with training sessions rather than run daily.
Outcome:: Reached for on lagging muscle-group focus cycles — users who want to bias the IGF signal locally to a specific region while maintaining systemic coverage. Same IGF-axis cautions apply: hypoglycemia risk, proliferation theoretical concern, no human data for the combination.

Reconstitution math

Reconstitution calculator

Calculated for a 1 mL U-100 insulin syringe (100 units/mL).

Peptide per vial

BAC water added

Desired dose

Units per dose

Draw to this mark on a U-100 syringe

Volume per dose: 0.2 mL
Doses per vial: 10
Concentration: 1 mg/mL

One vial lasts

Daily: 10 days
Every other day: 20 days
5×/week: 14 days

Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.

From the studies

Side effects from research

There is no human safety data for PEG-MGF — the points below come from what is known about the IGF-1 axis and about PEGylated compounds generally.

Because both the base mechanism and the conjugate are largely unstudied, even the intended effects are uncertain, and commonly reported user effects are anecdotal. Two theoretical concerns are worth naming: repeated PEG exposure can provoke anti-PEG antibodies in some people (potentially reducing effect or causing reactions), and the general IGF-axis concern — that sustained pro-proliferation signaling could theoretically promote tumor growth — applies here and is amplified by the longer-acting, systemic design. No human organ-overgrowth or long-term data exist.

Sources:PMID 27775236 PMID 20130113

As reported in literature

Research dosing ranges

There are no published dosing studies for PEG-MGF specifically — essentially all primary research used unmodified MGF. The figures below are therefore the parent-compound findings (animal/cell-culture), shown so research is never mistaken for a human PEG-MGF dose, plus the one robust point about the conjugate: PEGylation prolongs circulating time. Read alongside the contradiction that an independent replication found no unique activity for the synthetic MGF peptide. No reliable human half-life for the conjugate has been published.

Dose	Route	Model	Outcome	Sources:
In vitro	Cell-culture media	Myoblasts (parent MGF, Goldspink group)	Parent MGF reported to increase proliferation / activate satellite cells	PMID 20130113
In vitro	Cell-culture media	Myoblasts (independent replication)	Synthetic MGF E-domain peptide showed NO unique biological activity	PMID 24253050
N/A (chemistry)	Conjugate property	PEGylation principle	PEG chain slows enzymatic/renal clearance → longer circulating half-life than parent	PMID 27775236

Quick answers

Frequently asked

What is PEG-MGF?

PEG-MGF is MGF (Mechano-Growth Factor) with a polyethylene-glycol (PEG) chain attached to make it last longer. The PEG shield slows the enzymes and kidneys that normally clear the peptide within minutes, turning MGF's brief local pulse into a longer-acting, more systemic version. It is sold as a research reagent, not a medicine.

What is the difference between PEG-MGF and regular MGF?

Same peptide core, opposite lifespans. Plain MGF degrades in minutes, so it is dosed often, post-workout, and often near the worked muscle for a brief local effect. PEG-MGF is shielded by its PEG chain, so it lasts much longer, is dosed only about twice a week, and is meant to act throughout the body. Note that almost all the underlying biology was studied on plain MGF, not the PEGylated form.

Does PEG-MGF really last 2–3 days?

That figure is community and vendor lore — it cannot be traced to a published human pharmacokinetic study. What is well-supported is only the direction: PEGylation reliably makes a peptide last longer than its unmodified parent. The exact human half-life of PEG-MGF has never been measured in a citable study, so treat any specific number as unverified.

Is the science behind PEG-MGF solid?

No — it carries two layers of uncertainty. First, MGF's core mechanism is contested: an independent study found the synthetic peptide had no unique activity, no native free version has been isolated, and its receptor is unknown. Second, essentially all the research used unmodified MGF, not the PEGylated form, so claims specific to PEG-MGF are largely untested.

What are anti-PEG antibodies and should I worry about them?

Anti-PEG antibodies are immune proteins the body can produce in response to repeated exposure to polyethylene-glycol — the polymer chain that makes PEG-MGF longer-lasting. Pre-existing low-level anti-PEG antibodies are common in the general population from PEG in foods and cosmetics. With repeated injectable PEGylated dosing, those antibodies can rise and may reduce the drug's effect or cause reactions over time. It is a recognized pharmacology concern for PEGylated drugs in general; it has not been specifically characterized for PEG-MGF.

Is PEG-MGF an approved drug?

No. It has no approved human therapeutic use and has never been tested in humans as a therapy. It is a research reagent, and it is prohibited in sport by WADA (Section S2.3, which explicitly names mechano growth factors). This page presents research literature only and makes no medical claims.

Primary sources

References

PMID 20130113Matheny et al. 2010 (MGF / IGF-1 E-domain review)
PMID 24253050Fornaro et al. 2014 (no unique activity for synthetic E-peptide)
PMID 27775236PEGylation pharmacology review (extended half-life rationale)
PubChem CID 175675731PubChem CID 175675731 (MGF 24-AA core peptide)
WADA S2WADA Prohibited List S2

Research use only · Not medical advice · Updated 2026-06-01